|
Lupus Erythematosus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Transgelin-2 is upregulated on activated B-cells and expressed in hyperplastic follicles in lupus erythematosus patients.
|
28910360 |
2017 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
TAGLN2 is a candidate prognostic biomarker promoting tumorigenesis in human gliomas.
|
29110682 |
2017 |
|
Pancreatic carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer.
|
30041673 |
2018 |
|
Malignant neoplasm of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer.
|
30041673 |
2018 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Transgelin-2 is highly expressed in PDAC tissues compared with adjacent normal tissues.
|
30041673 |
2018 |
|
Tumor Cell Invasion
|
0.090 |
AlteredExpression
|
phenotype |
BEFREE |
Transgelin 2 overexpression inhibits cervical cancer cell invasion and migration.
|
30942422 |
2019 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Transgelin 2 has recently been shown to induce drug resistance, tumor migration, and invasion.
|
31488699 |
2019 |
|
Adult Liver Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility.
|
21577206 |
2011 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility.
|
21577206 |
2011 |
|
Malignant neoplasm of liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility.
|
21577206 |
2011 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Abnormal expression of TAGLN2 was observed in various types of cancer.
|
31485630 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Abnormal expression of TAGLN2 was observed in various types of cancer.
|
31485630 |
2019 |
|
Secondary malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Additionally, overexpression of TAGLN2 suppressed lung metastasis in a mouse model.
|
31485630 |
2019 |
|
Malignant neoplasm of breast
|
0.060 |
Biomarker
|
disease |
BEFREE |
Additionally, western blotting and reverse transcription‑quantitative polymerase chain reaction were performed to further explore the potential pathway in which TAGLN2 may be involved and the mechanism underlying its effects in breast cancer metastasis.
|
31485630 |
2019 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Additionally, western blotting and reverse transcription‑quantitative polymerase chain reaction were performed to further explore the potential pathway in which TAGLN2 may be involved and the mechanism underlying its effects in breast cancer metastasis.
|
31485630 |
2019 |
|
Meningioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
After down-regulating the expression of TAGLN2, there were significantly decreased capacities of cells proliferation and colony formation of meningioma cells, meanwhile, cell invasion was significantly decreased but the apoptosis rate was increased.
|
29424888 |
2018 |
|
Adult Meningioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
After down-regulating the expression of TAGLN2, there were significantly decreased capacities of cells proliferation and colony formation of meningioma cells, meanwhile, cell invasion was significantly decreased but the apoptosis rate was increased.
|
29424888 |
2018 |
|
Meningioma, benign, no ICD-O subtype
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
After down-regulating the expression of TAGLN2, there were significantly decreased capacities of cells proliferation and colony formation of meningioma cells, meanwhile, cell invasion was significantly decreased but the apoptosis rate was increased.
|
29424888 |
2018 |
|
Neural Tube Defects
|
0.010 |
Biomarker
|
group |
BEFREE |
Among the identified VPA-responsive genes, some have been associated previously with NTDs or VPA effects [vinculin, metallothioneins 1 and 2 (Mt1, Mt2), keratin 1-18 (Krt1-18)], whereas others provide novel putative VPA targets, some of which are associated with processes relevant to neural tube formation and closure [transgelin 2 (Tagln2), thyroid hormone receptor interacting protein 6, galectin-1 (Lgals1), inhibitor of DNA binding 1 (Idb1), fatty acid synthase (Fasn), annexins A5 and A11 (Anxa5, Anxa11)], or with VPA effects or known molecular actions of VPA (Lgals1, Mt1, Mt2, Id1, Fasn, Anxa5, Anxa11, Krt1-18).
|
15345369 |
2004 |
|
Maxillary Sinus Squamous Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Both TAGLN2 and PNP mRNA expression levels were significantly upregulated in clinical MSSCC tumor tissues.
|
21701775 |
2011 |
|
Fibrosis, Liver
|
0.310 |
Biomarker
|
disease |
CTD_human |
Characterization of chemically induced liver injuries using gene co-expression modules.
|
25226513 |
2014 |
|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characterization of chemically induced liver injuries using gene co-expression modules.
|
25226513 |
2014 |
|
Liver Cirrhosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characterization of chemically induced liver injuries using gene co-expression modules.
|
25226513 |
2014 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Characterization of chemically induced liver injuries using gene co-expression modules.
|
25226513 |
2014 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
Characterization of chemically induced liver injuries using gene co-expression modules.
|
25226513 |
2014 |